Office of the National Drug Control Policy

The Executive Office of the President Office of the National Drug Control Policy is a civilian agency within the Executive Office that funds federal drug-control research, data analysis, and capacity-building initiatives through grants and contracts. The agency operates as both a grant-making and contracting entity, supporting the National Drug Control Strategy through research institutions, local government agencies, and specialized vendors.

The agency has awarded 570 federal contracts totaling $1.36 billion in combined potential value, with $1.31 billion obligated to date. Contract activity has declined sharply in recent years: 9 awards in 2022, 15 in 2023, 11 in 2024, 7 in 2025, and 4 year-to-date in 2026. The most recent contract award closed on September 28, 2026. The competitive landscape is highly fragmented across 217 distinct prime contractors. Over the last five years, the top-five contract awardees by count—Cq-Roll Call, Inc., Cision US Inc., Politico LLC, Tveyes Inc., and GBT US LLC, each with three awards—account for only 33 percent of recent awards, collectively valued at less than $300 thousand. By potential value, the top five are dominated by ICF Incorporated ($15.1 million across two awards), Williams, Adley & Company DC LLP ($3.1 million), and Biobot Analytics Inc. ($2.4 million), representing only 2 percent of combined potential value across the period. The set-aside mix is heavily skewed toward unrestricted awards: 92 percent carry no set-aside designation, with 8(a) Sole Source accounting for 4 percent and all other small-business categories combined representing 4 percent.

The agency has awarded 2,378 federal grants totaling $2.81 billion in combined federal dollars obligated since 2014. Grant activity has remained steady: 248 awards in 2021, 244 in 2022, 251 in 2023, 251 in 2024, and 229 in 2025. The most recent grant award closed on September 15, 2025. Grant recipients are highly fragmented across 319 distinct entities. Over the last five years, the top five recipients by award count and federal dollars—County Of Monroe, Mercyhurst University, County Of San Diego, County Of El Paso, and University Of Baltimore—collectively account for 4 percent of recent awards and 7 percent of federal dollars obligated, ranging from $17.9 million to $92.9 million per recipient. The grant portfolio is predominantly Project Grants (99 percent of awards), with Cooperative Agreements comprising 1 percent.

Current grant opportunities emphasize tribal capacity-building and drug supply surveillance. RD-ET-RDA-26-002, posted September 2, 2026, funds researchers to help Tribal communities identify emerging drug threats, open to Tribal governments, nonprofits, and public and private higher-education institutions with a due date of September 13, 2026. RD-AL-RDAAL-26-001, posted August 6, 2026, supports applied drug policy research experiences for graduate students and recent post-graduates to conduct analysis supporting the National Drug Control Strategy, open to nonprofits and higher-education institutions with a due date of September 6, 2026. Both are structured as Cooperative Agreements.